Duodenal mucosal ablation with irreversible electroporation in non-alcoholic fatty liver disease: Roadmap of the future treatment

doi:10.3748/wjg.v31.i32.109235

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=4

Aug 28, 2025 (publication date) through Aug 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Aug 28, 2025; 31(32): 109235
Published online Aug 28, 2025. doi: 10.3748/wjg.v31.i32.109235

Duodenal mucosal ablation with irreversible electroporation in non-alcoholic fatty liver disease: Roadmap of the future treatment

Khaled Mohamed Mohamed Koriem

Khaled Mohamed Mohamed Koriem, Department of Medical Physiology, Medical Research and Clinical Studies Institute, National Research Centre, Giza 12622, Egypt

Author contributions: Koriem KMM designed the overall concept and outline of the manuscript, contributed to the design of the manuscript, the writing and editing of the manuscript, and review of the literature.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Khaled Mohamed Mohamed Koriem, PhD, Professor, Department of Medical Physiology, Medical Research and Clinical Studies Institute, National Research Centre, 33 El-Buhouth Street, Dokki, P.O. Box, Giza 12622, Egypt. kkoriem@yahoo.com

Received: May 6, 2025
Revised: June 4, 2025
Accepted: July 30, 2025
Published online: August 28, 2025
Processing time: 115 Days and 11.1 Hours

Core Tip

Core Tip: The novel work by Yu et al on the feasibility and efficacy of duodenal mucosal ablation (DMA) with irreversible electroporation (IRE) in non-alcoholic fatty liver disease (NAFLD) rodents is thoroughly examined in this article. The duodenum repaired effectively two weeks after DMA with IRE, according to the study in a sophisticated manner. In NAFLD small rats, the detection of liver lipid deposition, serum lipid parameters, and enteroendocrine parameters such claudin and zonula ocludens-1 levels offer new opportunities for side-effects assessment and advanced therapy approaches.